Brazil launches R$1bn primary care investment programme
This article was originally published in Clinica
Executive Summary
Brazil has launched the first phase of a primary care investment programme, the ongoing funding of which will be tied to the delivery of new coverage, service quality and outcomes standards. The so-called “programme for the improvement of access and quality in primary care” (PMAQ-AB) has been given ringfenced funding of just over R$1bn (US$607,000m) to the end of 2012: R$104m in 2011 and R$900m in 2012. Up to 17,600 primary care units are to be established during the first phase of the programme and, depending on their performance, will each receive up to R$8,500 per month to reinvest directly in service accessibility and quality. The government has yet to draw up the specific quality indicators it will use to measure performance.
You may also be interested in...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.